Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move

Company Overview - Tempus AI has received FDA clearance for its updated cardiac-imaging platform, Tempus Pixel, which utilizes artificial intelligence to enhance the analysis of cardiac MRI images [1][2][3] - The platform provides precise numerical values for cardiac tissue characteristics, aiding in the detection of conditions such as fibrosis, inflammation, or swelling that may be missed by conventional imaging methods [2] Stock Performance - Following the FDA clearance, Tempus AI stock surged approximately 13% to $88.26, with earlier highs reaching $91.06, entering a profit-taking zone above a buy point of $74.83 [4] - The stock has shown strong performance, breaking out of a cup base pattern on August 15, and currently has a Digital Relative Strength Rating of 92, placing it in the top 8% of all stocks based on 12-month performance [4] Regulatory Milestone - The FDA clearance is highlighted as a significant regulatory achievement for Tempus, reinforcing the company's commitment to advancing AI-driven imaging technology that is both scientifically rigorous and clinically relevant [3]